Zobrazeno 1 - 3
of 3
pro vyhledávání: '"John Schneekloth"'
Autor:
Yong Yean Kim, Berkley Gryder, Ranuka Sinniah, Megan Peach, Jack Shern, Abdalla Abdelmaksoud, Silvia Pomella, Girma Woldemichael, Benjamin Stanton, David Milewski, Joe Barchi, John Schneekloth, Raj Chari, Joshua Kowalczyk, Shilpa Shenoy, Jason Evans, Young Song, Chaoyu Wang, Xinyu Wen, Hsien-chao Chou, Vineela Gangalapudi, Dominic Esposito, Jane Jones, Lauren Procter, Maura O’Neill, Lisa Jenkins, Jun Wei, James McMahon, Barry O'Keefe, Robert Hawley, Javed Khan
Fusion-positive alveolar rhabdomyosarcoma (FP-RMS) is an aggressive pediatric sarcoma driven primarily by the PAX3-FOXO1 fusion oncogene, for which therapies targeting PAX3-FOXO1 are lacking. We screened 62,643 compounds using an engineered cell line
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d62a8ff91d6979ef44bb529876590bc7
https://doi.org/10.21203/rs.3.rs-2298627/v1
https://doi.org/10.21203/rs.3.rs-2298627/v1
Autor:
Yong Yean Kim, Girma Woldemichael, Berkley Gryder, Silvia Pomella, Ranuka Sinniah, Josh Kowalczyk, Young Song, Mehal Churiwal, Joseph Barchi, John Schneekloth, Xinyu Wen, Hsein-Chao Chou, Barry Okeefe, John Shern, Robert Hawley, Javed Khan
Publikováno v:
Cancer Research. 82:703-703
BACKGROUND: The PAX3/7-FOXO1 (P3F) fusion transcription factor is the oncogenic driver in fusion-positive rhabdomyosarcoma (FP-RMS). P3F drives oncogenesis in FP-RMS through transcriptional modulation of downstream target genes. Thus, P3F represents
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::09638220cb10ffeb1af36d676302df37
https://doi.org/10.1158/1538-7445.am2022-703
https://doi.org/10.1158/1538-7445.am2022-703
Autor:
John Schneekloth, Martin Pettersson
Discover a new paradigm in drug discovery that greatly expands the space of addressable drug targets and potential novel drugs Existing paradigms for drug discovery have focused largely on enzymes and other proteins as drug targets. In recent years,